[144] Akero Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Akero Therapeutics (AKRO) submitted a Form 144 reporting the proposed sale of 50,000 shares of common stock via J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value reported as $2,414,000 and approximately 79,988,975 shares outstanding. The filing shows the shares were acquired by a stock option exercise and the acquisition date, payment date and approximate sale date are all listed as 08/12/2025, with payment in cash.

The form discloses no securities sold in the past three months and includes the seller’s representation about not possessing undisclosed material adverse information. Several issuer/filer identification fields in the provided content are blank, so the filing text here omits the named filer and named person for whose account the securities are to be sold.

Positive

• Transaction disclosed under Rule 144, showing formal compliance with regulatory notice requirements
• Use of a major broker (J.P. Morgan Securities LLC) and listing of the securities exchange (NASDAQ)
• Acquisition and payment details provided: stock option exercise, payment in cash, with dates shown

Negative

• Key identification fields are blank in the provided content (filer CIK/CCC and named person for whose account the securities are to be sold), limiting context
• Acquisition and sale occur on the same date (08/12/2025), indicating immediate monetization of exercised options as presented in the filing extract

Insights

Financial Analyst

TL;DR: A small, disclosed insider sale — 50,000 shares (~$2.41M) — following an option exercise; size is immaterial versus outstanding shares.

The filing shows an option exercise and same-day proposed sale of 50,000 shares with aggregate market value of $2,414,000 against 79,988,975 shares outstanding, which represents roughly 0.063% of outstanding stock. The transaction was routed through J.P. Morgan Securities LLC on NASDAQ and paid in cash. From a market-impact standpoint, the disclosed size is immaterial to capitalization; from an execution standpoint, the use of Rule 144 and a major broker are routine compliance steps. The form content lacks explicit filer identification in the provided text, limiting assessment of insider role and timing context.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 mechanics, but the filing extract omits key identification fields needed for full governance context.

The document explicitly records acquisition by stock option exercise and a proposed sale on the same date, with the seller certifying absence of undisclosed material adverse information and relying on Rule 144 procedures. These elements suggest procedural compliance. However, critical identification fields (filer CIK/CCC and the named person for whose account the securities are to be sold) are blank in the supplied text, which constrains evaluation of insider status, blackout-period compliance, or any pre-existing trading plans.

08/12/2025 - 04:59 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017	50000	2414000	79988975	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/12/2025	Stock Option Exercise	Issuer			50000	08/12/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares did Akero Therapeutics (AKRO) file to sell on Form 144?

The filing lists 50,000 shares of common stock with an aggregate market value of $2,414,000.

When were the shares acquired and when is the approximate sale date listed for AKRO?

The filing shows the shares were acquired by stock option exercise on 08/12/2025 and the approximate date of sale is also listed as 08/12/2025.

Which broker and exchange are named in the AKRO Form 144?

The broker is J.P. Morgan Securities LLC and the securities exchange listed is NASDAQ.

Does the filing show any AKRO securities sold in the past three months?

The filing content states Nothing to Report for securities sold during the past three months.

What was the nature of the acquisition for the AKRO shares being sold?

The shares were acquired through a stock option exercise and payment was made in cash as shown in the filing.